Amid WeWork's bankruptcy woes, Adam Neumann seeks control with a $600 million offer through Flow. The battle intensifies as creditors weigh options amidst cash shortages and leadership skepticism.
Explore the latest findings from Barinthus Biotherapeutics on VTP-200's performance in the APOLLO trial for low-grade cervical lesions linked to persistent hrHPV infection. Positive trends were noted, though not statistically significant. No major safety concerns were observed.
Discover the impact of Brexit on UK drug shortages. Insights from a recent Nuffield Trust study reveal a doubling in shortages since 2020. Learn about challenges in medicine supplies, regulatory hurdles, and global disruptions.
WHO alerts the global community about tainted children's cough syrup by Johnson & Johnson. Elevated toxin levels detected in Benylin syrup prompt recalls across Africa. Investigation is underway.
Novo Nordisk's acquisition of Cardior Pharmaceuticals clears regulatory hurdles, advancing cardiovascular treatment development with CDR132L. Learn about the promising phase 2 trials and strategic expansion. Deal expected to close Q2 2024.
Discover toplines results of Cerevel Therapeutics' Phase 3 TEMPO-3 trial for tavapadon in Parkinson's disease treatment. Statistically significant efficacy and safety findings were revealed.
Ocular Therapeutix's Phase 1 HELIOS study unveils Axpaxli's efficacy in treating non-proliferative diabetic retinopathy. Significant DRSS improvement with no worsening observed. Positive Phase 2 data for Paxtrava also disclosed, showing substantial reduction in intraocular pressure.